Christian Britschgi

SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial

Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet et al. · Journal of Clinical Oncology · 2021 · 341 citations

Medicine, Oncology, Pharmacotherapy +13

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors

Kimberley M. Heinhuis, Matteo S. Carlino, Markus Joerger et al. · JAMA Oncology · 2019 · 92 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study

Sabine Schmid, Dirk Klingbiel, Stefanie Aeppli et al. · Lung Cancer · 2019 · 56 citations

Medicine, Pharmacology, Pharmacotherapy +8

Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients

Paulino Tallón de Lara, Virginia Cecconi, Stefanie Hiltbrunner et al. · Clinical Cancer Research · 2018 · 55 citations · Full text

Medicine, Oncology, Pharmacology +17